GLOW peptide is a lyophilized three-component research vial containing BPC-157, TB-500 and GHK-Cu at 70mg total. The three compounds are chemically unrelated and act on separate characterised targets: VEGFR2 and its downstream Akt-eNOS axis, monomeric globular actin, and copper(II) coordination in dermal fibroblasts.
Specification Table
GLOW Blend 70mg composition and verified component chemistry
| Property |
Value |
| Product format |
Lyophilized powder, single vial |
| Total peptide content |
70 mg |
| Component 1 |
BPC-157 |
| Component 2 |
TB-500 (thymosin β4) |
| Component 3 |
GHK-Cu |
| Component ratio |
Not published on the product record. Confirm against the certificate of analysis |
| CAS, GHK-Cu |
89030-95-5 |
| CAS, BPC-157 |
137525-51-0 |
| CAS, TB-500 / thymosin β4 |
77591-33-4 |
| CAS, KPV |
67727-97-3 |
| MW, GHK-Cu |
401.91 g/mol |
| MW, BPC-157 |
1419.55 g/mol |
| MW, thymosin β4 |
4963.55 g/mol |
| MW, KPV |
342.43 g/mol |
| Sequence, BPC-157 |
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Sequence, GHK-Cu |
Gly-His-Lys, copper(II) complex |
| Residue count, thymosin β4 |
43 |
| Target, BPC-157 |
VEGFR2, with downstream Akt and eNOS activation |
| Target, TB-500 |
Monomeric globular actin (G-actin), via the LKKTETQ motif |
| Target, GHK-Cu |
Copper(II) coordination and dermal fibroblast collagen synthesis |
| Appearance |
Blue to blue-violet lyophilized cake, from the GHK-Cu component |
| Purity |
Per lot-specific certificate of analysis |
| Solubility |
Soluble in bacteriostatic and sterile water |
| Storage, lyophilized |
-20°C, protected from light and moisture |
| Storage, reconstituted |
2-8°C, protected from light |
| Buffer incompatibility |
EDTA and other chelators strip copper(II) from the GHK-Cu component |
| Reconstituted stability |
Not established for this three-component mixture |
| Regulatory status |
No approved human or veterinary formulation for any component |
What Is in GLOW Peptide?
Three compounds, none of them chemically related to the others. That is the first thing worth establishing, because the name suggests a single substance and the vial contains a mixture.
BPC-157 is a fifteen-residue partial sequence of a protein found in human gastric juice. Hsieh and colleagues reported that it raises VEGFR2 expression in human vascular endothelial cells without raising VEGF-A, promotes receptor internalisation, and produces time-dependent activation of the VEGFR2-Akt-eNOS axis (Hsieh et al., 2017).
TB-500 refers to thymosin β4, a 43-residue intrinsically disordered peptide whose defining property is high-affinity binding to monomeric globular actin. It sequesters G-actin through a seven-residue motif, LKKTETQ, holding monomer out of the polymerising pool.
GHK-Cu is a copper-coordinated tripeptide, glycyl-L-histidyl-L-lysine bound to copper(II). Maquart and colleagues reported stimulation of collagen synthesis in cultured dermal fibroblasts across picomolar to nanomolar concentrations, with a control tripeptide inactive under identical conditions (Maquart et al., 1988).
Vascular signalling, cytoskeletal dynamics and matrix protein synthesis: three processes with three separate literatures, gathered into one vial.
What Is GLOW Peptide Used For in Published Research?
Each component individually has a research application. The combination, as supplied, does not have a published one, and that distinction is the honest answer to the question.
BPC-157 appears extensively across rodent tendon, muscle and gastrointestinal work, and that body of literature is the largest of the three. Chang and colleagues reported accelerated outgrowth from rat Achilles tendon explants, increased tendon fibroblast survival under hydrogen peroxide stress, and concentration-dependent increases in fibroblast migration (Chang et al., 2011).
Thymosin β4 turns up wherever actin dynamics matter, which covers cell migration, cytoskeletal remodelling and regulation of the monomer pool alike. Huff and colleagues reviewed that biology comprehensively.
GHK-Cu research centres on dermal fibroblasts and matrix synthesis. More recent work extends into transcriptomic modulation across a broad gene set.
No published study examines the three together in one shared model system. The combination is mechanistically coherent, since matrix construction, vascular support and cytoskeletal mobility genuinely do operate together in tissue. Coherence is not evidence, and the distinction matters when writing up any finding from this vial.
Why Is the Ratio Not Stated, and Why Does It Matter?
The product record gives a total of 70mg without a component breakdown, which is a genuine gap rather than an oversight this page can fill.
It matters because the three components differ enormously in molecular weight, which makes mass a poor guide to composition. GHK-Cu is 401.91. KPV, for comparison in the sibling KLOW product, is 342.43. BPC-157 is 1419.55. Thymosin β4 is 4963.55, more than twelve times heavier than GHK-Cu.
A consequence follows directly. An equal-mass split would deliver roughly twelve times more GHK-Cu molecules than thymosin β4 molecules. Receptor occupancy, enzyme kinetics and stoichiometric binding all scale with molar concentration rather than mass, so a design working from the label total is working from the wrong number.
Request the breakdown from the lot-specific certificate of analysis before any quantitative work. Without it the molar composition is unknown. Comparison against single-component preparations then cannot be normalised at all.
Does the Copper Component Affect the Others?
It is a reasonable question and nobody has published an answer for this formulation, so what follows is inference from composition rather than measurement.
Copper(II) is redox-active and can catalyse oxidation of susceptible amino acid residues, principally cysteine, methionine, tryptophan, tyrosine and histidine. Reading the component sequences tells you which are exposed.
BPC-157 runs Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Not one of those five vulnerable residues appears. On composition grounds it should be comparatively resistant.
Thymosin β4 is different. At 43 residues it contains a methionine, and methionine is the most readily oxidised of the group. Whether that occurs at a meaningful rate in a lyophilized cake containing copper is unmeasured, though a dry matrix suppresses the chemistry considerably relative to solution.
The practical implication is that reconstituted material deserves more caution than the dry cake, and that a preparation held in solution for an extended period is the condition where this question would first show up.
How Should GLOW Peptide Be Reconstituted?
Introduce diluent slowly against the vial wall rather than directing it onto the cake, then swirl gently until the solution clears. Shaking produces shear and foaming, and both degrade peptides.
Bacteriostatic water suits multi-draw preparations while sterile water suits single use. The choice affects working stability and belongs in the record rather than being assumed later.
Copper handling brings two further requirements. Protect the solution from light, because copper(II) complexes are photosensitive and can drive reactive oxygen chemistry under illumination. And check any downstream buffer for chelating agents, because EDTA binds copper more tightly than the tripeptide does and will strip it, leaving free GHK and a copper-EDTA species.
The reconstituted solution should be blue to blue-violet. That colour comes from the copper centre and is a first-order indicator the GHK-Cu component is intact. Loss of colour means loss of copper.
How Should Component Contributions Be Separated?
Three peptides in one vial means any observed effect has at least three possible sources plus their interactions, and the blend alone cannot resolve which.
Single-component arms are the only real answer. BPC-157, thymosin β4 and GHK-Cu are each available separately, and running them individually alongside the blend allows the combined effect to be compared against the sum of the parts. Anything short of that cannot separate additive behaviour from interaction.
A copper salt control belongs in the design as well. GHK-Cu carries copper(II) and the other two components do not, so any copper-dependent effect tracks with the GHK-Cu arm and is easily mistaken for tripeptide activity. Matching molar copper concentration with a simple salt separates metal from peptide.
Order of addition matters more than most designs allow for. Adding components sequentially rather than as a premixed solution can change behaviour, and with a copper-containing component present the sequence determines what the other peptides are exposed to and for how long.
None of this is exotic experimental design. It is the standard set of controls for any combination product, and it is routinely skipped because the blend is convenient and the controls are not.
What Should a Certificate of Analysis Cover?
For a three-component blend the certificate needs to establish more than it would for a single peptide, and knowing what to ask for saves an argument later.
Component breakdown comes first, expressed in milligrams per component rather than as a single total figure. Without it the molar composition is unknown and no quantitative design is possible.
Individual purity for each component follows that. A single blended purity figure averages across three peptides and hides a problem in any one of them.
Copper content by elemental analysis establishes stoichiometry for the GHK-Cu portion. Peptide purity figures cannot report it.
Counterion identity affects the mass-to-mole conversion for each component separately, and water content by Karl Fischer inflates apparent mass across the whole preparation.
A certificate covering all five is uncommon. Asking for it tells you something about the supplier as well as about the lot.
Handling and Storage in Laboratory Practice
Lyophilized material sits at -20°C, sealed against light and moisture. Reconstituted solution goes to 2-8°C shielded from light, aliquoted before freezing to avoid repeated freeze-thaw.
Documentation carries unusual weight for a three-component vial. Record lot number, diluent identity and volume, preparation date, findinging total concentration and storage conditions. Because the three peptides dissolve together and cannot be separated afterward, an anomaly attributable to one component cannot be isolated retrospectively without contemporaneous notes.
Discard and log any solution showing cloudiness, particulate matter, or a shift away from the expected blue-violet. A colour change in this formulation is chemically informative rather than cosmetic, and it should be recorded rather than simply replaced.
Published Literature
Every reference below was confirmed against the publisher record or a primary index. Each covers a single component. None covers the three in combination.
- Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. FEBS Letters. 1988;238(2):343-346.
- Pickart L, Margolina A. International Journal of Molecular Sciences. 2018;19(7):1987. PMID: 29986520
- Hsieh MJ, Liu HT, Wang CN, et al. Journal of Molecular Medicine. 2017;95(3):323-333.
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. Journal of Applied Physiology. 2011;110(3):774-780. PMID: 21030672
- Huff T, Müller CS, Otto AM, Netzker R, Hannappel E. International Journal of Biochemistry and Cell Biology. 2001;33(3):205-220.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. Gastroenterology. 2008;134(1):166-178.
Frequently Asked Questions
What is GLOW peptide?
A lyophilized three-component research vial holding BPC-157, TB-500 and GHK-Cu at 70mg in total. The three are chemically unrelated and act on separate targets: VEGFR2 signalling, globular actin sequestration, and copper(II) coordination in dermal fibroblasts. Laboratory research use only.
What is in GLOW peptide exactly?
BPC-157, which is a fifteen-residue fragment of a gastric juice protein. TB-500, meaning the 43-residue peptide thymosin beta 4. And GHK-Cu, glycyl-L-histidyl-L-lysine coordinated to copper(II). Registry numbers are 137525-51-0, 77591-33-4 and 89030-95-5.
What is GLOW peptide used for in research?
Each component carries its own application and the combination as supplied does not have a published one, which is the honest answer. BPC-157 dominates the rodent tendon and gastrointestinal literature. Thymosin beta 4 appears wherever actin dynamics matter, and GHK-Cu work centres on dermal fibroblasts and matrix synthesis.
What is the ratio between the three components?
It is not stated on the product record, and that is a genuine gap rather than something this page can fill. It matters because the components differ enormously in molecular weight, from 401.91 for GHK-Cu up to 4963.55 for thymosin beta 4.
Why does molecular weight difference matter here?
Because receptor occupancy, enzyme kinetics and stoichiometric binding all scale with molar concentration rather than with mass, which means the 70mg label total describes weight rather than molecule count. The spread is twelvefold. A design reasoning from the label is reasoning from the wrong quantity entirely.
Why is the powder blue?
The GHK-Cu component. Copper(II) coordination produces d-d electronic transitions absorbing in the visible region, giving the blue to blue-violet colour. It doubles as an integrity check. A colourless preparation has lost its copper.
Does the copper affect the other two peptides?
Unmeasured for this formulation, though composition permits an inference worth stating. BPC-157 contains none of the five residues most vulnerable to copper-catalysed oxidation. Thymosin beta 4 contains a methionine, which is the most readily oxidised of them, though a dry cake suppresses the chemistry considerably relative to solution.
How should GLOW peptide be reconstituted?
Add diluent slowly down the vial wall, then swirl gently until clear. Do not shake, since shear and foaming both degrade peptides. Protect from light because the copper component is photosensitive, and check any downstream buffer for chelating agents first.
Why must EDTA be avoided?
It binds copper(II) more tightly than the tripeptide can, stripping the metal and leaving free GHK alongside a copper-EDTA species. Published activity is attributed to the intact complex. A chelator in the buffer therefore invalidates the experiment without producing any visible sign that anything went wrong.
What documentation should accompany this vial?
Lot number, diluent identity and volume, preparation date, total concentration and storage conditions, at minimum. Three peptides dissolve together and cannot be separated afterward. Without contemporaneous notes an anomaly attributable to one component cannot be isolated later, and the dataset becomes difficult to defend.
How should the three components be separated experimentally?
With single-component arms run alongside the blend, since all three are available separately and comparing the combined effect against the sum of individual effects is the only route to distinguishing addition from interaction. There is no shortcut here. Designs that skip it cannot support attribution claims.
Why include a copper salt control?
GHK-Cu carries copper(II) and the other two components do not, so any copper-dependent effect tracks with the GHK-Cu arm and gets mistaken for tripeptide activity. Match the molar copper concentration with a simple salt. That single control separates metal contribution from peptide contribution cleanly.
Does order of addition matter?
It can, and few designs control for it. Adding components sequentially rather than as a premixed solution changes what each peptide is exposed to and for how long, which matters more when one component carries a redox-active metal.
Compliance Statement
GLOW Blend 70mg is sold exclusively for laboratory research use. It is not a drug, food, or cosmetic product, and it is not a dietary product of any kind. It is not approved by the FDA or any comparable authority for human or veterinary use. This product is not intended to diagnose, treat, cure, or prevent any disease. It must not be given to humans or animals. Purchase is restricted to qualified researchers and institutions operating within applicable laws. All handling is the responsibility of the purchasing laboratory.
19 reviews for GLOW BLEND 70MG